Gw9662
GW9662 is a synthetic organic compound that functions as a selective antagonist of the peroxisome proliferator-activated receptor gamma (PPARγ). It is commonly used in scientific research applications.
Lab products found in correlation
25 protocols using gw9662
Molecular Mechanism of UCP2 Regulation
Comprehensive Autophagy and Signaling Pathway Analysis
The chemicals used in our experiments were: Bafilomycin A1 (Selleck, S1413), 3-MA (Selleck, S2767), Rapamycin (Selleck, S1039), MNNG (Selleck, E0157), NAC (Selleck, S1623), Cycloheximide (Selleck, S7418), DAPI (Beyotime, C1002), Recombinant Human IL-33 (R & D, 3625-IL), Pifithrin-α HBr (Selleck, E0157), 2-MeOE2 (Selleck, S1233), ML385 (Selleck, S8790), SR11302 (MCE, HY-15870), BAY 11 (Selleck, S2913), GW9662 (Selleck, S2915), IQ3 (Selleck, S0781), STAT3-IN-7 (Selleck, S0986), FH535 (Selleck, S7484).
Modulation of GPER1, ERs, and Signaling
Wnt/β-catenin and PPARγ Regulation of Osteogenesis
Antibodies against calponin 1 (#17819), runt‐related transcription factor 2 (RUNX2; #12556), β‐catenin (#8480), phospho‐β‐catenin (Ser675) (#9567), glycogen synthase kinase‐3β (GSK‐3β; #9315), phospho‐GSK‐3β (Ser9) (#9322) and histone‐H3 (#4499) were from Cell Signaling Technology, Inc. An antibody against α‐smooth muscle actin (α‐SMA; NBP2‐22120) was purchased from Novus Biologicals. An antibody against peroxisome proliferator‐activated receptor gamma (PPAR‐γ; sc‐7273) was purchased from Santa Cruz Biotechnology. An antibody against glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH; TA‐08) was purchased from ZSGB‐BIO.
Modeling Liver Injury in Mice
Evaluating Fibrosis Regulators in Cell Culture
Evaluating Kuhuang Injection's Hepatoprotective Effects
Cell Viability Assay with Rosiglitazone and GW9662
Therapeutic Compounds for Post-SAH Treatment
dimethyl sulfoxide (DMSO), and 51.3 ml phosphate-buffered saline (PBS) was added to the
mixture. Similarly, 10 mg GW9662 (Selleck), an inhibitor of PPARγ was dissolved in 3.6 ml
DMSO, and PBS (32.4 ml) was added to the mixture. A total of 10 mg of MK886 (Selleck), an
antagonist of FLAP was dissolved in 2.1 ml DMSO, and 18.9 ml PBS was added to the mixture.
The final concentrations of GW9662, MK886 and bexarotene were the same (1 mM). The
solution was injected intraperitoneally at 5 mg/kg bexarotene, 2 mg/kg GW9662, and 3 mg/kg
MK886 per day after SAH. The vehicle group solution was prepared in the same manner and
administered in the same volume, same route and same time course as above. These reagents
were used immediately after SAH and continued to be used once a day until the rats were
euthanized.
Antibody-based Protein Signaling Assay
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!